89 related articles for article (PubMed ID: 37569316)
1. In silico analysis of regulatory networks underlines the role of miR-10b-5p and its target BDNF in huntington's disease.
Müller S
Transl Neurodegener; 2014; 3():17. PubMed ID: 25210621
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice.
Langfelder P; Gao F; Wang N; Howland D; Kwak S; Vogt TF; Aaronson JS; Rosinski J; Coppola G; Horvath S; Yang XW
PLoS One; 2018; 13(1):e0190550. PubMed ID: 29324753
[TBL] [Abstract][Full Text] [Related]
3. Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96.
Ubhi K; Rockenstein E; Kragh C; Inglis C; Spencer B; Michael S; Mante M; Adame A; Galasko D; Masliah E
Eur J Neurosci; 2014 Mar; 39(6):1026-1041. PubMed ID: 24304186
[TBL] [Abstract][Full Text] [Related]
4. miR-196a provides antioxidative neuroprotection via USP15/Nrf2 regulation in Huntington's disease.
Chan SC; Tung CW; Lin CW; Tung YS; Wu PM; Cheng PH; Chen CM; Yang SH
Free Radic Biol Med; 2023 Nov; 209(Pt 2):292-300. PubMed ID: 37907121
[TBL] [Abstract][Full Text] [Related]
5. Selective vulnerability of layer 5a corticostriatal neurons in Huntington's disease.
Pressl C; Mätlik K; Kus L; Darnell P; Luo JD; Paul MR; Weiss AR; Liguore W; Carroll TS; Davis DA; McBride J; Heintz N
Neuron; 2024 Mar; 112(6):924-941.e10. PubMed ID: 38237588
[TBL] [Abstract][Full Text] [Related]
6. Alterations in Cerebrospinal Fluid Urea Occur in Late Manifest Huntington's Disease.
Pfalzer AC; Shiino S; Silverman J; Codreanu SG; Sherrod SD; McLean JA; Claassen DO
J Huntingtons Dis; 2024; 13(1):103-111. PubMed ID: 38461512
[TBL] [Abstract][Full Text] [Related]
7. Amendment of Altered Immune Response by Curcumin in Drosophila Model of Huntington's Disease.
Dhankhar J; Shrivastava A; Agrawal N
J Huntingtons Dis; 2023; 12(4):335-354. PubMed ID: 37781812
[TBL] [Abstract][Full Text] [Related]
8. Novel Metabolic Abnormalities in the Tricarboxylic Acid Cycle in Peripheral Cells From Huntington's Disease Patients.
Naseri NN; Bonica J; Xu H; Park LC; Arjomand J; Chen Z; Gibson GE
PLoS One; 2016; 11(9):e0160384. PubMed ID: 27611087
[TBL] [Abstract][Full Text] [Related]
9. miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington's Disease Monkey Neural Cells.
Kunkanjanawan T; Carter RL; Prucha MS; Yang J; Parnpai R; Chan AW
PLoS One; 2016; 11(9):e0162788. PubMed ID: 27631085
[TBL] [Abstract][Full Text] [Related]
10. RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA.
Aguiar S; van der Gaag B; Cortese FAB
Transl Neurodegener; 2017; 6():30. PubMed ID: 29209494
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Functional Analysis Distinguishes Pathogenic, Nonpathogenic, and Compensatory Transcriptional Changes in Neurodegeneration.
Al-Ramahi I; Lu B; Di Paola S; Pang K; de Haro M; Peluso I; Gallego-Flores T; Malik NT; Erikson K; Bleiberg BA; Avalos M; Fan G; Rivers LE; Laitman AM; Diaz-García JR; Hild M; Palacino J; Liu Z; Medina DL; Botas J
Cell Syst; 2018 Jul; 7(1):28-40.e4. PubMed ID: 29936182
[TBL] [Abstract][Full Text] [Related]
12. The Emerging Role of microRNAs in Polyglutamine Diseases.
Dong X; Cong S
Front Mol Neurosci; 2019; 12():156. PubMed ID: 31275113
[TBL] [Abstract][Full Text] [Related]
13. Molecule of the month: miRNA and Huntington's disease (HD).
Shapshak P
Bioinformation; 2013; 9(11):549-50. PubMed ID: 23888093
[No Abstract] [Full Text] [Related]
14. Non-coding RNAs and neuroinflammation: implications for neurological disorders.
Chen Y; Mateski J; Gerace L; Wheeler J; Burl J; Prakash B; Svedin C; Amrick R; Adams BD
Exp Biol Med (Maywood); 2024; 249():10120. PubMed ID: 38463392
[TBL] [Abstract][Full Text] [Related]
15. The ubiquitin thioesterase YOD1 ameliorates mutant Huntingtin induced pathology in Drosophila.
Farkas A; Zsindely N; Nagy G; Kovács L; Deák P; Bodai L
Sci Rep; 2023 Dec; 13(1):21951. PubMed ID: 38081944
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated miRNA and mRNA Expression Affect Overlapping Pathways in a Huntington's Disease Model.
Zsindely N; Nagy G; Siági F; Farkas A; Bodai L
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569316
[TBL] [Abstract][Full Text] [Related]
17. Altered microRNA regulation in Huntington's disease models.
Lee ST; Chu K; Im WS; Yoon HJ; Im JY; Park JE; Park KH; Jung KH; Lee SK; Kim M; Roh JK
Exp Neurol; 2011 Jan; 227(1):172-9. PubMed ID: 21035445
[TBL] [Abstract][Full Text] [Related]
18. TRAX Provides Neuroprotection for Huntington's Disease Via Modulating a Novel Subset of MicroRNAs.
Weng YT; Chen HM; Chien T; Chiu FL; Kuo HC; Chern Y
Mov Disord; 2022 Oct; 37(10):2008-2020. PubMed ID: 35997316
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
